About the Company
We do not have any company description for Cabaletta Bio, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Cabaletta Bio, Inc.
230,161 Shares in Cabaletta Bio, Inc. (NASDAQ:CABA) Acquired by ...
Cabaletta Bio Trading Up 7.2 % NASDAQ CABA opened at $1.34 on Friday. The company has a market capitalization of $68.00 million, a PE ratio of -0.62 and a beta of 2.44. Cabaletta Bio, Inc. has a ...
CABALETTA BIO INC (CABA.MX) - Yahoo Finance
Cabaletta Bio Announces Pricing of Public Offering of Securities PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage ...
Charles Schwab Investment Management Inc. Sells 16,585 Shares of ...
Cabaletta Bio, Inc. has a 12 month low of $1.16 and a 12 month high of $19.04. The firm has a market capitalization of $57.19 million, a price-to-earnings ratio of -0.54 and a beta of 2.58.
Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
Detailed price information for Cabaletta Bio Inc (CABA-Q) from The Globe and Mail including charting and trades.
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why
Cabaletta Bio, Inc. (CABA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- ...
CABA | Cabaletta Bio Inc. Profile | MarketWatch
Company Profile Cabaletta Bio Inc. 2929 Arch Street Suite 600 Philadelphia, Pennsylvania 19104 ...
Individual investors who have a significant stake must be disappointed ...
To get a sense of who is truly in control of Cabaletta Bio, Inc. (NASDAQ:CABA), it is important to understand the ownership structure of the business. With 59% stake, individual investors possess ...
Cabaletta Bio Reports Q3 2024 Financial Results - Markets Insider
Cabaletta Bio, Inc. ( (CABA)) has released its Q3 earnings. Here is a breakdown of the information Cabaletta Bio, Inc. presented to its investors. Don't Miss our Black Friday Offers: Cabaletta Bio ...
Cabaletta Bio, Inc. (CABA): Why Are Analysts Loving This Shorted Stock ...
Cabaletta Bio, Inc. (NASDAQ:CABA) is a Pennsylvania based firm developing treatments for immune system diseases. Its primary drug that could end up generating millions in revenue is the CABA-201 drug.
Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing ...
Collaboration with intent to validate Cellares’ Cell Shuttle platform for manufacturing of CABA-201, Cabaletta Bio’s fully human CD19-CAR T product candidate, which is being evaluated in ...
Similar Companies
Loading the latest forecasts...